Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine

This publication has 9 references indexed in Scilit:

• Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease
  Leukemia, 2011
• Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
  Blood, 2008
• Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
  Proceedings of the National Academy of Sciences, 2004
• Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues
  Cancer Immunology, Immunotherapy, 2002
• Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients
  Leukemia, 2002
• WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.
  1994
• WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia
  Blood, 1994
• Expression of the Wilms' tumor gene (WT1) in human leukemias.
  1992
• Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts
  New England Journal of Medicine, 1979